SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing extreme volatility and a parabolic rally driven by intense speculative interest, aggressive price target hikes from analysts, and widespread community discussion regarding a potential stock split. While bulls point to high demand for AI-related storage as a justification for the surge, many market participants are debating whether the rapid valuation increase is a sustainable trend or an overextended bubble prone to a sharp reversal.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently experiencing heightened volatility and intense community debate following a now-deleted social media post from Michael Burry that sparked concerns regarding competition from Anthropic. While bears argue that Anthropic's rapid growth threatens Palantirs enterprise moat and long-term valuation, bulls are actively using the price drop as a buying opportunity, emphasizing that Palantir's integrated data platform and government contracts remain distinct, secure, and irreplaceable assets.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is seeing intense community debate as the stock experiences extreme volatility driven by a massive surge in AI hyperscaler demand, leading to reports of the company being sold out of capacity through 2028. While retail traders are capitalizing on its parabolic momentum, vocal skeptics and short sellers argue that the company's valuation has detached from its fundamental revenue and cash flow, labeling the current price action an AI-driven bubble.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow ($NOW) is facing intense selling pressure as investors grapple with concerns regarding AI-driven disruption and sector-wide budget constraints, despite management's recent insider buying and positive long-term growth outlooks. The community remains deeply divided, with some viewing the current price action as an overreaction to 'AI fear' and a generational buying opportunity, while others warn of a structural decline in the traditional software business model.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing a surge in investor confidence driven by major strategic partnerships, including a multiyear collaboration with Google on AI infrastructure and reported participation in Elon Musk's Terafab project. The community is actively discussing the stock's significant momentum as it hits multiyear highs, with many speculating on future foundry deals while bears caution against potential overextension and volatility.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

Dash is experiencing significant momentum driven by rumors of a major partnership with POL and the broader resurgence of interest in privacy-focused assets following recent performance in peer tokens like Zcash. The community is actively discussing potential breakout levels and the asset's utility, with many traders optimistic that the privacy sector is entering a period of renewed market attention.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy Enterprises is experiencing intense volatility following the announcement of preliminary Q1 revenue results and record manufacturing output, triggering significant debate among traders regarding the company's long-term execution versus its history of missed guidance. While some investors see a compelling accumulation opportunity at lower valuations, others are highlighting concerns over product performance, class action litigation, and the sustainability of production costs.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending as investors weigh significant long-term capital investments, including a recent transatlantic partnership with Blykalla AB, against the company's aggressive and technically challenging timeline to hit criticality by mid-2026. The community is deeply divided between bulls focused on the strategic de-risking of regulatory hurdles and the urgency of AI data center energy needs, and skeptics emphasizing the stock's pre-revenue status, significant insider selling, and the inherent execution risks of advanced nuclear deployment.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

Aircoin is gaining significant community momentum on Solana as users highlight its commitment to long-term holding through a unique voluntary supply-locking mechanism. Supporters are actively contrasting the project's consistent seven-month development and community-driven treasury against short-lived speculative trends in the current meme sector.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is currently trending as a leading AI infrastructure play, driven by massive hyperscaler contracts with Meta and Microsoft and a strategic pivot toward becoming a full-stack 'Neocloud' provider. The community is actively debating the company's ambitious 2026 revenue targets, its potential acquisition of AI21 Labs to bolster its enterprise orchestration capabilities, and its ability to maintain strong price action despite broader market volatility and geopolitical tensions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Pfizer reported positive Phase 2b topline results for its GLP-1 candidate in adults with obesity or overweight without type 2 diabetes.</li><li>The company plans to launch more than 20 trials in 2026, including 10 Phase 3 studies of PF’3944.</li><li>For the fourth-quarter (Q4), Pfizer posted a revenue of $17.6 billion, beating Wall Street estimates of $16.8 billion, according to Fiscal.ai data.</li></ul>Pfizer Inc. (PFE) stock was in the spotlight on Tuesday after the company reported positive updates from a study testing weight loss treatment and a better-than expected fourth quarter print.However, <a href="https://stocktwits.com/symbol/PFE">PFE shares</a> were down 2% in pre-market trading on Tuesday as investors appeared to remain cautious about growth risks and the long road ahead for its GLP-1 pipeline.&nbsp;<h2 class="st-heading-2">Positive Topline Results For Weight Loss Treatment&nbsp;</h2>Pfizer reported positive topline results from its Phase 2b VESPER-3 study evaluating PF’3944, an ultra-long-acting injectable GLP-1 receptor agonist, in adults with obesity or overweight without type 2 diabetes.The trial aimed to determine whether patients could maintain weight loss while switching from weekly to once-monthly injections and whether the treatment would retain a favorable safety profile.The study met its primary endpoint, delivering statistically significant weight reduction across all tested doses. Participants achieved up to 12.3% mean placebo-adjusted weight loss at week 28. PF’3944 was generally well tolerated, with mostly mild to moderate gastrointestinal side effects and limited treatment discontinuations. The safety profile remained consistent with the broader GLP-1 drug class.“Based on the monthly dosing efficacy and tolerability demonstrated in this trial, we remain confident in our plan to include a higher 9.6 mg monthly maintenance dose of PF’3944 in Phase 3,” said Jim List, Chief Internal Medicine Officer.Following its acquisition of Metsera and a global licensing deal with YaoPharma, Pfizer said it is accelerating its obesity treatment pipeline. The company plans to launch more than 20 trials in 2026, including 10 Phase 3 studies of PF’3944.<h2 class="st-heading-2">Q4 Earnings Snapshot</h2>Pfizer reaffirmed its full-year 2026 revenue guidance of $59.5 billion to $62.5 billion and adjusted diluted earnings between $2.80 and $3 per share. The company said the outlook includes roughly $5 billion in expected COVID-19 product sales and a projected $1.5 billion year-over-year revenue hit from certain products losing exclusivity.The company posted a 2% decline in FY2025 revenue at $62.6 billion with adjusted earnings of $3.22 per share.For the fourth-quarter (Q4), Pfizer posted a revenue of $17.6 billion, beating Wall Street estimates of $16.8 billion, according to Fiscal.ai data. It also posted a better-than-expected EPS of $0.66.<h2 class="st-heading-2">What Did Stocktwits Users Say?</h2>Retail sentiment on Stocktwits remained in the ‘bullish’ territory over the past 24 hours, amid ‘high’ message volumes. PFE was among the top trending tickers on the platform.<figure class="image"><img src="https://news.stocktwits-cdn.com/PFE_jpg_91e98a5cdf.webp" alt="PFE.jpg" width="928" height="111"><figcaption>PFE's Sentiment Meter and Message Volumes in Pre-Market on Feb. 3, 2026 | Source: Stocktwits</figcaption></figure>One user expects multiple upcoming catalysts this year for the stock.<stembedurl>https://stocktwits.com/giuseppe8469/message/643776399</stembedurl>Another user highlighted key support and resistance levels.<stembedurl>https://stocktwits.com/Jas45z/message/643776263</stembedurl>The stock has gained around 1.5% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/sofi-stock-rises-pre-market-what-moving-average-indicates/cZbiqlvR4ln">SOFI Stock Hovers Around 200-DMA — A Make-or-Break Test Looms</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Pfizer’s logo is on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Pfizer Reports Positive Weight-Loss Trial Results, Strong Q4 – So Why Is PFE Stock Falling?

Pfizer reaffirmed its full-year 2026 revenue guidance of $59.5 billion to $62.5 billion, while its FY2025 revenue came in at $62.6 billion.

Equity

Pharma ETF (FTXH) Hits New 52-Week High

Pharma ETF FTXH hits a new 52-week high as industry momentum, rate cuts, and AI adoption lift the sector???signaling potential near-term upside for FTXH investors.



Pharma ETFs in Spotlight Following Robust Q3 Earnings Results

Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.

Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month 

As National Alzheimer's Awareness Month spotlights new treatments, healthcare ETFs like XLV and VHT might gain fresh investor appeal.  

ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook

 JNJ's Q3 earnings beat and raised 2025 sales outlook could lift healthcare ETFs like IHE, XLV and IYH, heavily weighted toward the drugmaker.


Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit

Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.     

ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook

IHE, PPH, XLV, IYH and FTXH could gain as JNJ lifts 2025 outlook and dividend after strong Q2 earnings beat.


What Are Wall Street Analysts' Target Price for Bristol-Myers Squibb Stock?

Pharma giant Bristol-Myers Squibb has notably outpaced the broader pharma industry over the past year and analysts remain moderately bullish on the stock’s prospects.

FTXH
First Trust Exchange-Traded Fund III - First Trust Nasdaq Pharmaceuticals ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest FTXH News

FTXHFirst Trust Exchange-Traded Fund III - First Trust Nasdaq Pharmaceuticals ETF